Table 4 Odds ratios (ORs) of treatment-related grade ≥ 3 adverse events
Advese event (grade ≥ 3) | Trials (N) | Availability | Effect OR(95% CI) | P value | Heterogeneity | Analysis model | ||
|---|---|---|---|---|---|---|---|---|
Weekly (events/total) | Triweekly (events/total) | I2 value | P value | |||||
Haematological | ||||||||
 Anaemia | 5 | 19/710 | 17/1269 | 1.63 (0.84–3.15) | 0.15 | 24% | 0.26 | Fixed effect |
 Thrombocytopenia | 6 | 40/755 | 19/1297 | 3.49 (1.98–6.16) |  < 0.0001 | 0% | 0.78 | Fixed effect |
 Neutropenia | 4 | 64/572 | 69/978 | 1.48 (1.02–2.15) | 0.04 | 0% | 0.87 | Fixed effect |
 Leukopenia | 4 | 139/657 | 179/1213 | 1.50 (1.16–1.93) | 0.002 | 0% | 0.46 | Fixed effect |
Non-haematological | ||||||||
 Nephrotoxicity/Renal dysfunction | 5 | 3/702 | 2/1241 | 1.37 (0.32–5.81) | 0.67 | 29% | 0.24 | Fixed effect |
 Nausea/Vomiting/Constipation/Diarrhea | 7 | 124/816 | 240/1334 | 0.83 (0.41–1.68) | 0.61 | 76% | 0.0003 | Random effect |
 Skin reaction/Dermatitis/Rash | 6 | 33/771 | 41/1306 | 1.00 (0.62–1.62) | 1 | 0% | 0.56 | Fixed effect |
 Mucositis/Stomatitis | 7 | 188/816 | 280/1334 | 0.87 (0.69–1.09) | 0.23 | 46% | 0.08 | Fixed effect |
 Xerostomia | 2 | 16/339 | 20/350 | 0.83 (0.42–1.62) | 0.58 | 0% | 0.56 | Fixed effect |
 Ototoxicity | 3 | 3/387 | 7/517 | 0.51 (0.14–1.87) | 0.31 | 0% | 0.86 | Fixed effect |